Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology

 Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of
                      the American Society of Hematology

PR Newswire

PALO ALTO, Calif., Dec. 12, 2012

PALO ALTO, Calif., Dec. 12, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK)
announced today the publication of a clinical trial abstract in the
proceedings of the 54^th Annual Meeting of the American Society of Hematology
in Atlanta, Georgia. The abstract, "Oral Ezatiostat HCl (Telintra), a
Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with
Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by
Roger M. Lyons, MD; Sharon T. Wilks, MD; and of David J. Friedman MD, PhD, of
Cancer Care Centers of South Texas, US Oncology in San Antonio, Texas; and
Shelby A. Young, RN, BSN, and Gail L. Brown, MD, of Telik, Inc., in Palo Alto,
California, is available online at Blood (ASH Annual Meeting Abstracts) 2012
120: Abstract 4394.

This abstract reports the preliminary results of a clinical trial with
ezatiostat to study the treatment of patients with idiopathic chronic
neutropenia (ICN). ICN is a rare group of blood disorders characterized by
low circulating neutrophils, recurrent fevers, mucosal inflammation and
serious systemic infections. The risk and severity of these complications is
related to abnormally low levels of white blood cells. Most patients
initially respond to treatment with granulocyte colony stimulating factors
(G‑CSF); however, some patients fail to respond or become resistant to G‑CSF
treatments. Further, G‑CSF therapy is often associated with bone and muscle
pain, low platelet counts and enlargement of the spleen. Patients may need to
be on G‑CSF for the rest of their lives, and these side effects can interfere
with therapy.

Ezatiostat is an investigational agent in development for the treatment of
ICN. The compound is a glutathione S-transferase (GST) inhibitor that
activates Jun kinase, which has been demonstrated to promote growth and
maturation of hematopoietic progenitors. Four patients with  longstanding,
severe ICN and inadequate absolute neutrophil count (ANC) response to G‑CSF
were enrolled in this phase 2 trial. These patients all had a history of
frequent hospitalization for sepsis, prolonged courses of antibiotics and poor
response to myeloid growth factors, including G‑CSF. The patients were
treated with orally administered ezatiostat.

Ezatiostat treatment of these ICN patients with grade 4 neutropenia who were
not responsive to G‑CSF resulted in a durable increase in their
white-blood-cell levels, leading to clinically significant reductions in
serious infections. Extended oral treatment with ezatiostat has been well
tolerated in these patients and may be appropriate for longer-term therapy.
Ezatiostat is the first targeted GSTP1-1 inhibitor that has been shown to
have a positive effect on white blood cell levels in ICN and may provide
molecular insight into the pathophysiology of ICN. These results suggest that
further study is warranted of ezatiostat's potential role as an oral therapy
alternative or adjunct to G‑CSF in the treatment of ICN in patients who are
not responsive to G‑CSF.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company
focused on discovering and developing small molecule drugs to treat cancer.
The company's most advanced drug candidate is Telintra, a modified
glutathione analog intended for the treatment of hematologic diseases
including myelodysplastic syndrome and ICN; followed by Telcyta®, a cancer
activated prodrug for the treatment of a variety of cancers. Telik's product
candidates were discovered using its proprietary drug discovery technology,
TRAP®, which enables the rapid and efficient discovery of small molecule drug
candidates.

This press release contains "forward-looking" statements regarding the safety
and effectiveness of Telintra in treating ICN, whether Telintra treatment
results in a durable increase in white blood cell levels, the tolerability of
Telintra in ICN patients and Telintra's potential role as an oral therapy
alternative or adjunct to G‑CSF in the treatment of ICN. These
forward-looking statements are based upon Telik's current expectations, and
there are important factors that could cause actual results to differ
materially from those indicated by these forward-looking statements. Detailed
information regarding factors that may cause actual results to differ
materially from the results expressed or implied by statements in this press
release may be found in Telik's periodic filings with the Securities and
Exchange Commission, including the factors described in the section entitled
"Risk Factors" in its quarterly report on Form 10-Q for the quarter ending
September 30, 2012. Telik does not undertake any obligation to update
forward-looking statements contained in this press release.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered
trademarks of Telik, Inc.

SOURCE Telik, Inc.

Website: http://www.telik.com
Contact: Denise San Bartolome, Corporate Communications, Telik, Inc.,
+1-650-845-7712, denisesb@telik.com
 
Press spacebar to pause and continue. Press esc to stop.